Progenics Pharmaceuticals (NASDAQ: PGNX) is one of 283 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its rivals? We will compare Progenics Pharmaceuticals to related businesses based on the strength of its earnings, risk, analyst recommendations, valuation, institutional ownership, dividends and profitability.
This table compares Progenics Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Progenics Pharmaceuticals Competitors||-5,616.95%||-481.94%||-40.11%|
Institutional and Insider Ownership
89.2% of Progenics Pharmaceuticals shares are held by institutional investors. Comparatively, 49.9% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 3.6% of Progenics Pharmaceuticals shares are held by insiders. Comparatively, 17.2% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
This is a summary of current ratings and target prices for Progenics Pharmaceuticals and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Progenics Pharmaceuticals Competitors||804||3164||11461||230||2.71|
Progenics Pharmaceuticals currently has a consensus price target of $13.20, indicating a potential upside of 136.14%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 43.96%. Given Progenics Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts plainly believe Progenics Pharmaceuticals is more favorable than its rivals.
Earnings & Valuation
This table compares Progenics Pharmaceuticals and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Progenics Pharmaceuticals||$69.43 million||$10.80 million||-7.08|
|Progenics Pharmaceuticals Competitors||$286.20 million||$34.74 million||131.06|
Progenics Pharmaceuticals’ rivals have higher revenue and earnings than Progenics Pharmaceuticals. Progenics Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Risk and Volatility
Progenics Pharmaceuticals has a beta of 3.5, meaning that its stock price is 250% more volatile than the S&P 500. Comparatively, Progenics Pharmaceuticals’ rivals have a beta of 1.28, meaning that their average stock price is 28% more volatile than the S&P 500.
Progenics Pharmaceuticals beats its rivals on 9 of the 12 factors compared.
About Progenics Pharmaceuticals
Progenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The Company’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools. It also includes commercial product, RELISTOR (methylnaltrexone bromide) for opioid-induced constipation. AZEDRA is a radiotherapeutic product candidate in development as a treatment for malignant and/or recurrent pheochromocytoma and paraganglioma, rare tumors found in the adrenal glands and outside of the adrenal glands, respectively. RELISTOR is a treatment for opioid induced constipation. PyL is a clinical-stage, fluorinated PSMA-targeted Positron Emission Topography (PET) imaging agent for prostate cancer. PSMA TTC is a thorium-227 labeled PSMA-targeted antibody therapeutic.
Receive News & Ratings for Progenics Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.